Called $NBIS bullish on May 13, 2025: $NBIS rose 267% in 5 months.
View call →Long-term investor. BSc in Economics, MSc in Finance. Equity Analyst with a focus on Fundamental Analysis and Valuation.
Cite asCryptoQuant has tracked the directional calls on HIMS by @mvcinvesting on Substack since Mar 2025: not yet scored on HIMS (as of Nov 18, 2026).
9 HIMS calls on record, a thin history.
Relative view by default: fewer than 30 HIMS calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @substack:mvcinvesting to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
Portfolio Update: Recap of 2025
Nebius remains a top-conviction holding with further catalysts and execution beating even bullish expectations.
View original →Hims & Hers (HIMS): Q2 2025 Earnings Review
Yesterday, HIMS reported its Q2 2025 results. For the first time in the company’s history, it missed analysts’ expectations. The stock is down ~13% so far. Overreaction or justified? In this article, I’ll break down everything you need to know from the Earnings Report. Subscribe now Financial and Business Highlights Revenue : $544.8M vs. $552.1M est. (+73% YoY) This marks a sharp deceleration from the 111% YoY growth in Q1, though it was expected given the decline in revenue from compounded GLP-1s, which has been the main growth driver. Breaking it down: Compounded GLP-1s : ~34.9% of total revenue (from ~39.2% in Q1) This is trending down both in percentage terms and in absolute dollars (from $230M to $190M QoQ). That’s a positive sign IMO, it suggests HIMS is slowing its aggressive push to sell as many GLP-1s as possible, something that has recently brought significant litigation risk. However, GLP-1s still represent too large a share of total revenue, which remains a key concern. The company also stated it expects continued growth across all weight-loss specialties, including GLP-1s, indicating they will keep pursuing the 503A compounding loophole, something I’ve been openly critical of. Core business : ~65.1% of total revenue Core business YoY growth slowed from “nearly 30%” in Q1 to “nearly 20%” in Q2, not a great sign. The deceleration was somewhat expected due to marketing spend being shifted toward compounded GLP-1s, but here’s the issue: GLP-1 revenue actually decreased QoQ, and marketing spend fell in absolute terms. That probably means customer acquisition costs (CAC) for the core business are rising. Last quarter, the company said: “We're seeing more subscribers come to our platform through organic and other lower-cost channels.” They even suggested the core business could reaccelerate after the semaglutide shortage ended, but that’s not showing up in the numbers. From yesterday’s earnings call: “We see continued robust subscriber growth across our dermatology, oral weight loss and daily sexual health offerings that all sustained YoY subscriber growth rates above 55% in the second quarter. Strong performance across these offerings helped offset headwinds that came from offboarding GLP-1 subscribers on commercially available dosages as well as a decline in our on-demand sexual health subscriber base.” This helps explain the sharp slowdown in the core business. HIMS has never broken down revenue by treatment category, which would be extremely useful. I suspect that erectile dysfunction (ED) treatments still make up a meaningful share of the core business. There’s no shame in that, it’s how the company started, but the drop in the on-demand sexual health subscriber base likely played a big role in the slowdown. The move toward daily treatments is a known strategy and likely aimed at differentiating from competitors like Amazon, which has been aggressively pursuing the ED market with cheaper, equally convenient options. Hopefully, HIMS can reaccelerate the core business while building a healthier revenue mix with less ED dependency. As management noted: “We expect headwinds from the rotation of our sexual health specialty toward more premium daily offerings for the next couple of quarters but are excited to see over 40% of total sexual health subscribers and roughly 65% of new sexual health subscribers in the quarter benefiting from a daily offering.” That’s encouraging, but it also means headwinds will persist in the near term. Long term, though, this shift could improve retention rates and prove to be a net positive, provided core business growth picks back up. Subscribers : 2,439M (+31% YoY) This was the lowest quarterly net adds since Q2 2023, reinforcing the idea that CAC may be rising. Competition could also be an important factor. Personalized Subscribers as a % of Total Subscribers increased by less than 1% from Q1 to just above 60%, the slowest pace ever. While that’s still progress towa
View original →Portfolio Update – 06/30/2025 – H1 Review
Many NBIS catalysts remain ahead and valuation stays cheap even after a large rally.
View original →Hims & Hers (HIMS): Q1 2025 Earnings Review
Yesterday, HIMS reported its Q1 2025 results. Yesterday, HIMS reported its Q1 2025 results.
View original →(Important) Portfolio Update – 04/04/2025
Litigation risk, a broken 200-day average and high short interest point to more near-term HIMS downside.
View original →